Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Mersana Therapeutics Inc (NASDAQ: MRSN) closed at $0.34 down -1.52% from its previous closing price of $0.35. In other words, the price has decreased by -$1.52 from its previous closing price. On the day, 1.54 million shares were traded.
Ratios:
For a deeper understanding of Mersana Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.83 and its Current Ratio is at 1.83.
JP Morgan Upgraded its Underweight to Neutral on March 19, 2024, while the target price for the stock was maintained at $5.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 16 ’25 when Mandelia Ashish sold 3,554 shares for $0.58 per share. The transaction valued at 2,061 led to the insider holds 57,519 shares of the business.
Protopapas Anna sold 8,637 shares of MRSN for $5,009 on Jan 16 ’25. The Director now owns 168,041 shares after completing the transaction at $0.58 per share. On Jan 16 ’25, another insider, Lowinger Timothy B, who serves as the SVP, Chief Sci.&Tech. Officer of the company, sold 8,048 shares for $0.58 each. As a result, the insider received 4,668 and left with 257,673 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.26.
Stock Price History:
Over the past 52 weeks, MRSN has reached a high of $2.83, while it has fallen to a 52-week low of $0.26. The 50-Day Moving Average of the stock is -3.99%, while the 200-Day Moving Average is calculated to be -71.40%.
Shares Statistics:
A total of 124.63M shares are outstanding, with a floating share count of 96.84M. Insiders hold about 22.30% of the company’s shares, while institutions hold 50.21% stake in the company.
Earnings Estimates
A comprehensive evaluation of Mersana Therapeutics Inc (MRSN) is underway, with the input of 5.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.03 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.27 and -$0.76 for the fiscal current year, implying an average EPS of -$0.6. EPS for the following year is -$0.64, with 5.0 analysts recommending between -$0.13 and -$0.95.
Revenue Estimates
A total of 9 analysts have provided revenue estimates for MRSN’s current fiscal year. The highest revenue estimate was $34.8M, while the lowest revenue estimate was $2.75M, resulting in an average revenue estimate of $22.16M. In the same quarter a year ago, actual revenue was $40.5M
